Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

来源 :World Journal of Clinical Oncology | 被引量 : 0次 | 上传用户:javashhai2
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Pancreatic cancer(PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in borderline resectable and locally advanced PC. Second line treatments showed to positively affect both overall survival and quality of life in fit patients affected by metastatic disease. At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, thus, current clinical practice does not include them. Up to now, despite the fact of extremely promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease. Pancreatic cancer (PC) would become the second leading cause of cancer death in the near future, and even representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in Borderline resectable and locally advanced PC. affect both overall survival and quality of life in fit patients affected by metasta At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, and, current clinical practice does not include them. Up to now, despite the fact of Extreme promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease.
其他文献
原 文  园中有树,其上有蝉。蝉高居悲①鸣饮露,不知螳螂在其后也;螳螂委身曲附②欲取蝉,而不知黄雀在其傍也;黄雀延③颈欲啄螳螂,而不知弹丸在其下也。此三者皆务④欲得其前利,而不顾⑤其后之有患也。  ——选自《说苑》  朗 读  园中/有树,其上/有蝉。蝉/高居悲鸣/饮露,不知/螳螂/在其后也;螳螂/委身曲附/欲取蝉,而不知/黄雀/在其傍也;黄雀/延颈/欲啄螳螂,而不知/弹丸/在其下也。 此三者/皆
期刊
请下载后查看,本文暂不支持在线获取查看简介。 Please download to view, this article does not support online access to view profile.
一、突现教材之精美,让学生在美读中享受语文课本中每篇课文都是经过精选的,而每一篇好文章,总是以它的美好而真挚的情感来打动读者,从而激发读者心灵深处闪光的东西,使读者
我國的一些成语往往涉及了历史上的著名人物。例如:“凿壁借光”与学者匡衡有关,“望梅止渴”与三国的曹操有关,等等。下面的一些成语也与历史人物有关,你能说出来吗?请你把它填在对应的括号里。  1.单刀赴会——( )  2.纸上谈兵——( )  3.初出茅庐——( )  4.草木皆兵——( )  5.胸有成竹——( )  6.拔山扛鼎——( )  7.弄假成真——(
期刊
导语:  “霾”是谁?你认识它吗?它犯了什么错误,向谁认了错?霾又说了些什么?  “讨厌的雾,大白天开着车灯,我都不敢跑。”一辆汽车气愤地说。  “您别生气。我不过是悬浮在空气中的微小水滴,太阳出来稍微一晒我就消散了。”雾谦逊地说。  “快到中午了,你还不散,没看见车都堵了一大串了。”汽车不满地说。  “那不是因为我,那是霾闹的。”雾委屈地说。  “什么霾?还不是你雾在捣乱!”汽车说。  “我不过
期刊
今年5月23日至27日,河北省煤炭学会矿建专业委员会以《快速建井》为题,在秦皇岛市举行了学术报告会。特邀代表煤炭部基建总公司副总工程师张鹏耀,山东兖州煤研所高级工程师
家庭作业一直是教育工作者和广大家长极为关心的一个焦点问题,它为家庭参与和关心孩子的教育和学习问题提供了机会.随着教育改革的深入,家庭作业日益受到人们的关注.然而对于
第一部分丝素/醋酸纤维素同轴电纺膜的制备和材料表征分析  目的:  将丝素蛋白(SF)和聚乙二醇(PEO)以及醋酸纤维素(CA)作为原材料,利用同轴静电纺丝技术制备内层为CA,外层为SF/PEO
爸爸爱红烧肉  妈妈爱吃蛋糕  我爱吃冰激凌  可是  奇怪极了  我们三个人一起吃时  什么都好美味  原来  和家人一起  才能吃出甜蜜和幸福  汉字小课堂  古时候,人们用三个相同的符号表示“多”的意思,所以品字的本义指“众多”,后来引申为“品质”“品种”“风格”等意思。  有很多字的构造和“品”相似,例如“淼”“森”“众”“鑫”“晶”等,人们把这种字的结构叫作“品”字结构。我们大胆猜想,也
期刊
一、揭题引趣,提示学法题目是文章的眼睛,教学离不开审题,弄明白题意,文章的脉络也大致清楚了。当学生学习新课文时,总会围绕课题提出这样或那样的问题,而且还要知道如何学习